OCULAR THERAPEUTIX IN

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

09 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

07 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Appointment of New Board Member

12 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

10 Jun 2023 17:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

07 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

05 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update

08 May 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

28 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Report First Quarter 2023 Financial Results

24 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

14 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

06 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference

28 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results

21 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

11 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

06 Jan 2023 07:00:00 By Nasdaq GlobeNewswire